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ABSTRACT  
Objective: To compare various chelationtherapies used 
for thalassemia on basis of efficacy. 
Materials and Methods: The study included 80 patients 
of thalassemia which were divided in two groups, each 
comprising of 40 patients. Group 1 was administered 
orally with deferiprone, whereas, group 2 was injected 
with deferoxamine.  
Results: The patients had an average age of of 20.3 ± 4.3 
years. Out of 80 patients, 54 (67.5%) were male and 26 
(32.5%) were females. The average ferritin was found to 
be 2645 ± 1260 for all patients, whereas it was 2545 ± 
1232 for group 1 and 2822 ± 1235 for group 2. No 
significant difference was observed for ferritin level in 
both the groups (p value=0.232). The complications 
noted for patients included 18.2% IGT, 7.8% DM and 
28.7% hypothyroidism for all thalassemia patients. 
Conclusion: Both therapies showed equal efficiency in 
control of iron load in thalassemia patients.  
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INTRODUCTION  
Thalassemia is a hemoglobinopathy caused due to 
flaw in beta globulin chain production. Its 
symptoms include anemia and 
hepatosplenomegaly. The management of beta 
thalassemia mainly includes blood transfusion, 
which result in iron overload in various organs 
(American Diabetes Association 2017). To reduce 
iron load, iron chelators are used through oral and 
injectable means. The most common option of iron 
chelator is deferiprone, which is taken orally as 
compared to injectable desferoxamine, which 
reduced iron load from heart and endocrine system 
(Farmaki, Tzoumari & Pappa 2011). About 60% of 
the thalassemia patient face iron overload 
complication of endocrinopathies which involves at 
least one endocrine organ. Meagre amount of 
literature is present over comparison of iron 
chelators on the basis of effectiveness in treating 
beta-thalassemia (Rostami, Hatami & Shirkani 
2011). The present study aims to compare 
effectiveness of various oral and injectable 
chelators in terms of certain endocrinopathies such 
as hypothyroidism, impaired glucose tolerance 
(IGT) and diabetes mellitus (DM).     
MATERIALS AND METHODS  
This research work is an observational, prospective 
and cohort study. It was conducted at Surya Azeem 
Hospital, Lahore from 1st March 2018 to 1st March 
2019 and included 80 patients suffering from 
thalassemia. Patients with any respiratory, systemic 
or renal disorder and those taking long term 
antibiotic therapy were excluded. The patients were 
divided in two groups, each comprising of 40 
patients. In group 1, patients were administered 
with oral iron chelator of deferiprone, whereas in 
group 2, patients were given injectable iron 
chelator of deferoxamine.  
Demographics, clinical and diagnostic findings 
were noted. IGT was calculated followed by 
plasma glucose levels during fast. Moreover, PTH, 
serum calcium and phosphate level were also 
noted. Informed consent were collected from all 
patients. For statistical analysis, SPSS v.17 was 
used. Descriptive statistics included means and 
standard deviations. For qualitative variables, 
frequencies and percentages were calculated. Chi 
square test was used with p value of 0.05 regarded 
as significant. 
RESULTS 
The patients had an average age of 20.3 ± 4.3 
years. Out of 80 patients, 54 (67.5%) were male 
and 26 (32.5%) were females. The average ferritin 
was found to be 2645 ± 1260 for all patients, 
whereas it was 2545 ± 1232 for group 1 and 2822 ± 
1235 for group 2. No significant difference was 
observed for ferritin level in both the groups (p 
value=0.232). The complications noted for patients 
included 18.2% IGT, 7.8% DM and 28.7% 
hypothyroidism for all thalassemia patients. 
DISCUSSION  
The present study has evaluated efficacy as well as 
complications associated with both type of 
therapies. Before 1987, desferoxamine was the 
only iron chelator present. The adaptability of 
patients towards this therapy was poor on basis of 
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discomfort caused by daily dose and high cost. On 
the other hand, accessibility towards deferipone 
helped in attaining treatment acceptance. However, 
it is found that deferipone has less effectivity than 
deferoxamine in removal of iron from different 
organs.  
Most of the patients included in present study also 
comprised of endocrine disorder, where 
hypothyroidism was most common complication 
present in both the groups. On the other hand, DM 
was found more commonly in group 2 as compared 
to group 1. However, no significant difference was 
found between both the groups on basis of 
complications. On the other hand, no significant 
difference was found between both groups on basis 
of ferritin level. Thus, it cannot be said that which 
group has better efficiency than the other. This 
finding is supported by previous research works. It 
is recommended that oral therapy should be used 
with combination of deferipone and desferasirox to 
overcome ferritin levels in thalassemia patients. 
This recommendation has already been put forward 
in previous research of Farmaki et al. The 
combination therapy is found to be more efficient 
than individual ones and lowers ferritin level below 
the average in patients.   
CONCLUSION  
It can be concluded that both the therapies have 
equal effectiveness in managing iron overload in 
thalassemic patients. 
REFERENCES  
Alswaidi, F & O’Brien, S 2009, 'Premarital screening programmes for haemoglobinopathies, HIV and hepatitis 
viruses: review and factors affecting their success', J Med Screen, vol 16, pp. 22–8. 
American Diabetes Association 2017, ' Classification and diagnosis of diabetes', Diabetes Care, vol 40, pp. 11–
24. 
Anderson, L, Wonke, B, Prescott, E, Holden, S, Walker, J & Pennell, D 2002, 'Comparison of effects of oral 
deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular 
function in beta- thalassaemia', Lancet, vol 360, pp. 516–520. 
Angastiniotis, M & Hadjiminas, M 1981, 'Prevention of thalassemia in Cyprus', Lancet , vol 1, pp. 369–371. 
Aydinok, Y, Darcan, S, Polat, A, Kavakli, K, Nigli, G & Coker, M 2002, 'Endocrine complications in patients 
with β-thalassemia major', J Trop Pediatr, vol 48, pp. 50–54. 
Balocco, M, Carrara, P, Pinto, V & Forni, G 2010, 'Daily alternating deferasirox and deferiprone therapy for 
“hard-to-chelate” beta-thalassemia major patients', Am J Hematol, vol 85, pp. 460-1. 
Evered, D, Ormston, B, Smith, P, Hall, R & Bird, T 1973, 'Grade of hypothyroidism', BMJ, vol 1, pp. 657-662. 
Farmaki, K, Tzoumari, I & Pappa, C 2011, 'Oral chelators in transfusion-dependent thalassemia major patients 
may prevent or reverse iron overload complications', Blood Cells Mol Dis, vol 47, pp. 33-40. 
Galanello, R 2003, 'Deferiprone in the treatment of transfusiondependent thalassemia: a review and perspective', 
Ther Clin Risk Manag, vol 3, pp. 795- 805. 
Galanello, R & Origa, R 2010, 'Beta-thalassemia', Orphanet J Rare Dis , vol 21, pp. 5-11. 
Gulati, R, Bhatia, V & Agarwal, S 2000, 'Early onset of endocrine abnormalities in beta- thalassemia major in a 
developing country', J Pediatr Endocrinol Metab, vol 13, pp. 651–656. 
Kontoghiorghes, G, Aldouri, M & Sheppard, L 1987, 'I-2- dimethyl-3-hydroxypyrid-4- one an orally active 
chelator for treatment of iron overload', Lancet, vol 1, pp. 1294–1295. 
Neufeld, E 2006, 'Oral chelatorsdeferasirox and deferiprone for transfusional iron overload in thalassemia 
major: new data, new questions', Blood, vol 107, pp. 3436–3441. 
Piga, A, Roggero, S, Salussolia, I, Massano, D, Serra, M & Longo, F 2010, 'Deferiprone', Ann N Y Acad Sci , 
vol 1202, pp. 75–78. 
Rostami, P, Hatami, G & Shirkani, A 2011, 'Endocrine complications in patients with major β-thalassemia', 
Iranian South Med J, vol 4, pp. 240-245. 
Voskaridou, E, Anagnostopoulos, A, Konstantopoulos, K, Stoupa, E, Spyropoulou, E & Kiamouris, C 2006, 
'Zoledronic acid for the treatment of osteoporosis in patients with betathalassemia: results from a 
single-center, randomized, placebo-controlled trial', Haematologica, vol 91, pp. 1193–1202. 
Voskaridou, E, Christoulas, D & Terpos, E 2011, 'Successful chelation therapy with the combination of 
deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload 
after single-agent chelation therapies', Br J Haematol, vol 154, pp. 654-6. 
Wang, C, Wu, K, Tsai, F, Peng, C & Tsai, C 2006, 'Comparison of oral and subcutaneous iron chelation 
therapies in the prevention of major endocrinopathies in b-thalassemia major patients', Hemoglobin, vol 
30, pp. 257–262. 
 
